Boston Scientific's Cardio Comeback
The medical device maker Boston Scientific (BSX) announced Apr. 16 that it resolved quality problems at a facility in St. Paul, Minnesota, which were inherited from Guidant (GDT). The development shows how Boston Scientific CEO James R. Tobin is making headway on the project he took on when buying the company for $27 billion last year.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.